Corium Innovations to Present Transdermal Research at AAPS 2024 PHARMASCI 360 Annual Meeting

Grand Rapids, MI -- October 22, 2024 -- Corium Innovations, Inc., a leading full-service contract development and manufacturing organization specializing in novel drug delivery technologies, announced today that its transdermal research will be presented at the AAPS 2024 PHARMASCI 360 Annual Meeting, scheduled for October 20-23 at the Salt Palace Convention Center in Salt Lake City, UT, and hosted by the American Association of Pharmaceutical Scientists (AAPS).

Corium Innovations Formulation Scientist Pushkar Kulkarni, MS will present the poster “Use of In Silico Models to Predict In Vitro Skin Flux and Comparison with Experimental Results for Transdermal Drug Delivery” on October 22. This research highlights the innovative use of computational models to predict skin permeability and compares these predictions with experimental data, offering valuable insights for the development of transdermal drug delivery systems.

Poster Details:

• Title: Use of In Silico Models to Predict In Vitro Skin Flux and Comparison with Experimental Results for Transdermal Drug Delivery
• Authors: Pushkar Kulkarni and Julia Shvetz
• Poster No: T1530-01-06
• Date: Tuesday, October 22, 2024
• Time: 3:30 PM
• Forum No: 01
• Monitor No: 65

“We are thrilled to share our latest research findings at AAPS 2024 PHARMASCI 360,” said Niraj Vasisht, PhD., Chief Technical Officer at Corium Innovations. “Our work on in silico models represents a significant advancement in the field of transdermal drug delivery, and we look forward to engaging with fellow scientists and industry leaders at this prestigious event.”

About Corium Innovations

Headquartered in Grand Rapids, Michigan, Corium Innovations is a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies. With a track record spanning nearly 30 years, Corium Innovations offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and its proprietary proven drug delivery technology Corplex®. For more information, visit www.coriuminv.com.

About Gurnet Point Capital

Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. For more information, visit www.gurnetpointcapital.com.

About Webster Equity Partners

Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. For more information, visit www.websterequitypartners.com.

Contact

Gartman PR
gartmanpr@gmail.com
202-413-4226